Yimiao Shenzhou Honored Again: Ranked Among China's Top 100 Innovative Pharmaceutical and Biologics Companies in 2024
Imunopharm
Developer of Gene and Cell Therapy Technologies
Recently, the 8th Future Healthcare Ecosystem Exhibition was held at the Beijing Yiren Yichuang International Convention and Exhibition Center. During the event, the results of the "2024 Future Healthcare 100 Strong" were announced. Beijing Yimiaoshenzhou Medical Techology Co., Ltd. successfully made it to the main list of the "2024 Future Healthcare 100 Strong" — TOP 100 in China's Innovative Pharmaceuticals and Bioproducts category, thanks to its technological innovation capabilities and outstanding achievements in the CAR-T cell therapy field. This marks the fourth time that Yimiao Shenzhou has topped this authoritative list, fully demonstrating the industry's high recognition and widespread consensus on the company’s deep accumulation in the R&D of innovative CAR-T drugs.
The Future Healthcare 100 List, established in 2015 by VB100, Arterial Network, and Danke Research Institute, is the first list in China targeting non-listed companies in the innovative healthcare sector. It aims to select Chinese innovators who truly represent the future of healthcare, identify the core forces of China’s future healthcare industry, and promote the innovation and transformation of the health and medical industry. The selection for this top 100 list is based on key dimensions such as valuations by investment institutions, cumulative financing amounts, growth speed of enterprises, credit, and reputation.
In the past year, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. has made breakthrough progress in the clinical research of multiple CAR-T cell drugs, obtaining two clinical trial approvals for new CAR-T drugs targeting solid tumors. This further consolidates the company's leading position in the field of gene and cell therapy, bringing a ray of hope to countless patients with advanced cancer.
Looking ahead, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. will accelerate the clinical transformation and application of new drugs in the vast blue ocean of gene and cell therapy, write a brilliant chapter for China's innovative pharmaceutical enterprises, and contribute to the development of new productive forces in China's health industry.
// About Yimiao Shenzhou //
Founded in 2015, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. is headquartered in Beijing and has the mission of "making cancer no longer an incurable disease." It is a leading innovative pharmaceutical company in the clinical stage, focusing on applying cutting-edge gene and cell drug technologies to treat major diseases (such as cancer and autoimmune diseases). To date, the company has completed 9 rounds of strategic financing and owns a one-stop, self-developed gene and cell drug R&D and industrialization platform. It possesses several core technologies, won the highest prize at the finals of China's Disruptive Technology Innovation Competition, obtained clinical trial approvals for 5 Class 1 new drugs, and was granted Beijing’s first-ever Manufacturing License for gene and cell drugs. Its R&D pipeline covers hematological malignancies such as lymphoma, leukemia, and myeloma, as well as solid tumors including liver cancer, colorectal cancer, gastric cancer, and pancreatic cancer, making it a leader in the field of gene and cell drugs.
The company has undertaken more than 10 national and provincial-level scientific research projects, including the Special Research Project of the Ministry of Science and Technology's Key R&D Program, the "Open Challenge" technical project for cell therapy by the National Innovation Center, and the Beijing Municipal Science and Technology Major Special Project. It is a National High-tech Enterprise, a Beijing-based specialized and innovative enterprise, a Zhongguancun Frontier Technology Enterprise, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Workstation. The team has been honored with awards such as Beijing's New Science and Technology Star, Zhongguancun High-end Leading Talent, Beijing Haidian District Haiying Talent, Xinguomen Leading Talent, the Gold Award (First Place) at Tsinghua University’s President's Cup Innovation Challenge, MIT Technology Review's 35 Innovators Under 35, and Fortune Magazine’s 40 Under 40 Business Elites.
